Conference summary: Novel HIV therapies - From discovery to clinical proof of concept

AIDS Research and Human Retroviruses

Volumn 12, Issue 10, 1996, Pages 859-865

  Miller, Roger H ^a   Turk, Steven R ^a   Black, Roberta J ^a   Bridges, Sandra ^a   Sarver, Nava ^a,b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYCLIC NUCLEOSIDE; ADEFOVIR; CAPSID PROTEIN; CD4 ANTIGEN; DIDANOSINE; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTEGRASE; INTERLEUKIN 2; NEF PROTEIN; NEVIRAPINE; NUCLEIC ACID; PIPERAZINE DERIVATIVE; PROTEINASE; REGULATOR PROTEIN; REV PROTEIN; RIBONUCLEASE H; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIF PROTEIN; VIRUS ENVELOPE PROTEIN; VPR PROTEIN; VPU PROTEIN; ZALCITABINE; ZIDOVUDINE;

CONFERENCE PAPER; DRUG DESIGN; GENE THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL RESEARCH; MONKEY; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; VIRUS PATHOGENESIS;

EID: 0029957764     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1996.12.859     Document Type: Conference Paper

References (32)

1. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, and Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (London) 1995;373:123-126.
2. Wei X, Ghosh SK, Taylor ME, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature (London) 1995:373;117-122.
3. Heath SL, Tew JG, Tew JG, Szakal AK, and Burton GO: Follicular dendritic cells and human immunodeficiency virus infectivity. Nature (London) 1995;377:740-744.
4. + T cells are infectible by human immunodeficiency virus but do not release virus after activation. J Virol 1995;69:5659-5665.
5. Stevenson M, Stanwick TL, Dempsey MP, et al.: HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J 1990;9:1551-1560.
6. Zack JA, Arrigo SJ, Weitsman SR, et al.: HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure. Cell 1990;61:213-222.
7. Kovacs JA, Baseler M, Dewar RJ, et al.: Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N Engl J Med 1995;332:567-575.
8. Dickover RE, Garratty EM, Herman SA, et al.: Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission: Effect of maternal zidovudine treatment on viral load. JAMA 1996;275:599-605.
9. Connor EM, Sperling RS, Gelber R, et al.: Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-1180.
10. IIIB with reduced replication phenotypes. J Virol 1996 (in press).
11. Tsai C-C, Follis KE, Sabo A, et al.: Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 1995;270:1197-1199.
12. Rice WG, Supko JG, Malspeis L, et al.: Inhibitors of HIV nucleocapsid protein zinc fingers as candidates for the treatment of AIDS. Science 1995;270:1194-1197.
13. Miller RH and Sarver N: HIV accessory proteins: Emerging therapeutic targets. Mol Med 1995;1:479-485.
14. Schubert U, Bour S, Ferrer-Montiel AV, et al.: The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains. J Virol 1996;70:809-819.
15. Dubrovsky L, Ulrich P, Nuovo GJ, Manogue KR, Cerami A, and Bukrinsky M: Nuclear localization signal of HIV-1 as a novel target for therapeutic intervention. Mol Med 1995;1:217-230.
16. Riddell SR, Elliott M, Lewinsohn DA, et al.: T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nature Med 1996;2:216-223.
17. Wilson CC, Wong JT, Girard DD, et al.: Ex vivo expansion of CD4 lymphocytes from human immunodeficiency virus type 1-infected persons in the presence of combination antiretroviral agents. J Infect Dis 1995;172:88-96.
18. Bonyhadi ML, Rabin L, Salimi S, et al.: HIV induces thymus depletion in vivo. Nature (London) 1993;363:728-732.
19. Lee LA, Gritsch HA, Sergid JJ, et al.: Specific tolerance across a discordant xenogeneic transplantation barrier. Proc Natl Acad Sci USA 1994;91:10864-10867.
20. Walker RE, Blaese RM, Davey RT, et al.: A phase I/II pilot study of the safety of the adoptive transfer of syngeneic gene-modified cytotoxic T lymphocytes in HIV-infected identical twins. Hum Gene Ther 1996;7:367-400.
21. Lee S-W, Gallardo HF, Gilboa E, and Smith C: Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain. J Virol 1994;68:8254-8264.
22. Sarver N, Cantin EM, Chang PS, et al.: Ribozymes as potential anti-HIV-1 therapeutic agents. Science 1990;247:1222.
23. Yu M, Poeschla E, Yamada P, et al.: In vitro and in vivo characterization of a second functional hairpin ribozyme against HIV-1. Virology 1996;206:381-386.
24. Zhou C, Bahner IC, Larson G, et al.: Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes. Gene 1994;149:33-39.
25. Nabel GJ, Fox BA, Post L, et al.: A molecular genetic intervention for AIDS - effects of a transdominant negative form of Rev. Hum Gene Ther 1994;5:79-92.
26. Woffendin C, Ranga U, Yang Z-Y, et al.: Expression of a protective gene prolongs survival of T cells in HIV-infected patients. Proc Natl Acad Sci USA 1996 (in press).
27. Wolff JA, Malone RW, Williams P, et al.: Direct gene transfer into mouse muscle in vivo. Science 1990;247:1465-1468.
28. Wang B, Ugen KE, Srikantan V, et al.: Gene inoculation generates immune response against human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993;90:4155-4160.
29. Irwin MJ, Laube LS, Lee V, et al.: Direct injection of a recombinant retroviral vector induces human immunodeficiency virus-specific immune responses in mice and nonhuman primates. J Virol 1994;68:5036-5044.
30. Wang B, Boyer J, Srikantan V, et al.: Induction of humoral and cellular immune responses to the human immunodeficiency type 1 virus in nonhuman primates by in vivo DNA inoculation. Virology 1995;211:102-112.
31. IIIB Env/Rev proteins. AIDS 1995;9:43-50.
32. Jolly DJ, Merritt J, Kowal K, et al.: Direct administration of retroviral vectors as therapy for HIV-1 infection. AIDS Res Hum Retroviruses 1995;11(Suppl 1):8166. [Abstract 406]